Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study - 01/01/06
, Yulia Dyachkova a, Sebnem Pirildar b, Martin Anders c, Afaf Khalil d, Aleksander Araszkiewicz e, Tamara Shakhnovich f, Aly Akram g, Jan Pecenak h, Margaret McBride i, Tamas Treuer a
Corresponding author. Tel.: +43 1711 78 624; fax: +43 1711 78 551.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose. - Sexual dysfunction in patients with schizophrenia can reduce quality of life and treatment compliance. This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year.
Subjects and methods. - Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188).
Results. - Based on patient perception, the odds of experiencing sexual dysfunction during 1 year of therapy was significantly lower for patients treated with olanzapine and quetiapine when compared to patients who received risperidone or haloperidol (all P≤0.001). Females on olanzapine (14%) or quetiapine (8%) experienced a lower rate of menstrual irregularities, compared to females on risperidone (23%) or haloperidol (29%). Significant discordance was evident between patient reports and psychiatrist perception of sexual dysfunction, with psychiatrists underestimating sexual dysfunction (P≤0.001).
Conclusion. - These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia.
Le texte complet de cet article est disponible en PDF.Keywords : Schizophrenia, Sexual dysfunction, Hyperprolactinemia, Antipsychotic agents
Plan
Vol 21 - N° 4
P. 251-258 - juin 2006 Retour au numéro
Article précédent
- Differentiation of adoptees at high versus low genetic risk for schizophrenia by adjusted MMPI indices
- Virva Siira, Karl-Erik Wahlberg, Jouko Miettunen, Pekka Tienari, Kristian Làksy
- Source monitoring deficits in hallucinating compared to non-hallucinating patients with schizophrenia
- Jerome Brunelin, Marion Combris, Emmanuel Poulet, Lassad Kallel, Thierry D'Amato, Jean Dalery, Mohamed Saoud
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?